MANNKIND CORP Convertible Notes Payable
MANNKIND CORP (MNKD) had Convertible Notes Payable of $98.44 million as of 2013-12-31, per its 10-K filed 2014-03-03.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:ConvertibleNotesPayable · last filed 2014-03-03
- 2013-12-31: Convertible Notes Payable $98.44M.
- 2013-09-30: Convertible Notes Payable $213.12M.
- 2013-06-30: Convertible Notes Payable $212.75M.
- 2013-03-31: Convertible Notes Payable $212.38M.
| Period end | Convertible Notes Payable |
|---|---|
| 2013-12-31 | $98.44M 10-K · filed 2014-03-03 |
| 2013-09-30 | $213.12M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $212.75M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $212.38M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $212.03M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |